2016年11月4-6日，由广东省医学会主办，广东省医学会眼科分会、中山大学中山眼科中心承办2016年广东省医学会眼科学学术会议暨国际视网膜论坛，在美丽的广州花都隆重召开。会中，AME出版社的编辑很荣幸能邀请到迈阿密大学帕尔马眼科研究所的Philip J. Rosenfeld教授（图 1）分享OCTA 是如何运用到黄斑疾病诊断中的。
Rosenfeld教授认为，比起FFA和ICGA在黄斑病中的诊断，ZEISS 血流OCT可以更快更清晰地呈现眼底血管（包括脉络膜血管），同时成像范围更广，更利于对眼底疾病的诊断。在对 AMD 的早期诊断中，他介绍到使用ZEISS 血流OCT可以发现新生血管的伴发，而使用FFA是难以查见的。他相信，OCT 的使用会推进眼底领域影像技术，加深人们对眼底病的认识，并进一步促进眼底疾病的诊断和治疗。更多精彩观点请点击下方采访视频。
图1：迈阿密大学帕尔马眼科研究所Philip J. Rosenfeld教授
Could you briefly introduce yourself and your research interest?
The application of OCT Angiography in clinical practice
How does OCT Angiography diagnosis the dry AMD?
What are the advantages of OCT Angiography compared to those traditional imaging method of macular diseases?
What do you think of the future development of OCT Angiography?
Philip J. Rosenfeld, MD, PhD
Dr. Rosenfeld received both his MD and PhD degrees from the Johns Hopkins School of Medicine, and he completed a research fellowship and residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Following his residency, Dr. Rosenfeld completed a Vitreoretinal fellowship at the Bascom Palmer Eye Institute, University of Miami Miller School of Medicine. In 1996, he joined the faculty of the Bascom Palmer Eye Institute where he is now an associate professor of Ophthalmology. Dr. Rosenfeld is a member of the American Academy of Ophthalmology (AAO), the American Society of Retinal Specialists (ASRS), the Retina Society, the Macula Society, and the Association for Research in Vision and Ophthalmology (ARVO).
Dr. Rosenfeld specializes in medical and surgical diseases of the retina with a primary research interest in age-related macular degeneration. Since joining the faculty at the Bascom Palmer Eye Institute, Dr. Rosenfeld has been a principal investigator in several photodynamic therapy trials using verteporfin, as well as the Lucentis (Genentech) Phase I/II/III trials, the Macugen (pegaptanib, Eyetech) Phase II/III trials, and the Anecortave Acetate (RETAANE, Alcon) Phase II/III clinical trials. He is currently involved in additional clinical trials investigating other anti-angiogenic therapies for neovascular AMD including systemic bevacizumab (Avastin). He pioneered the use of intravitreal Avastin for the treatment of neovascular AMD and macular edema.